Evommune (EVMN) investor relations material

Addressing chronic inflammation and unmet medical needs

• Chronic inflammation is a leading cause of death globally, with annual direct costs of $90B and over 50% of current therapies failing patients.

• Focus is on developing next-generation therapies with distinct mechanisms to address critical gaps in care for immune-mediated diseases.

Pipeline and clinical development highlights

• Two lead programs in Phase 2: EVO756 (oral MRGPRX2 antagonist) for atopic dermatitis and migraine, and EVO301 (long-acting IL-18BP fusion protein) for atopic dermatitis.

• Multiple clinical data readouts are expected through 2028, including pivotal Phase 2b and Phase 3 trials.

• EVO756 demonstrated robust efficacy and favorable safety in Phase 1 and 2a trials, with broad anti-inflammatory potential and dual action on mast cells and sensory neurons.

• EVO301 achieved statistically significant efficacy and was well tolerated in a Phase 2a trial for atopic dermatitis, with a subcutaneous formulation advancing to Phase 2b.

Market opportunity and differentiation

• EVO756 targets multi-billion-dollar markets with potential first-line oral therapy status in atopic dermatitis and migraine, addressing large populations with high unmet need.

• EVO301 is positioned to capture substantial share in the growing atopic dermatitis biologics market, projected to reach $60B, by addressing broader disease drivers than current therapies.

• Both programs leverage differentiated mechanisms: EVO756 for neuroinflammation and mast cell activation, EVO301 for multi-pathway immunomodulation.